Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 May 21;9(1):252.
doi: 10.1186/1556-276X-9-252. eCollection 2014.

A sight on the current nanoparticle-based gene delivery vectors

Solmaz Maleki Dizaj  1 , Samira Jafari  1 , Ahmad Yari Khosroushahi  2
Affiliations

A sight on the current nanoparticle-based gene delivery vectors

Solmaz Maleki Dizaj et al. Nanoscale Res Lett. .

Abstract

Nowadays, gene delivery for therapeutic objects is considered one of the most promising strategies to cure both the genetic and acquired diseases of human. The design of efficient gene delivery vectors possessing the high transfection efficiencies and low cytotoxicity is considered the major challenge for delivering a target gene to specific tissues or cells. On this base, the investigations on non-viral gene vectors with the ability to overcome physiological barriers are increasing. Among the non-viral vectors, nanoparticles showed remarkable properties regarding gene delivery such as the ability to target the specific tissue or cells, protect target gene against nuclease degradation, improve DNA stability, and increase the transformation efficiency or safety. This review attempts to represent a current nanoparticle based on its lipid, polymer, hybrid, and inorganic properties. Among them, hybrids, as efficient vectors, are utilized in gene delivery in terms of materials (synthetic or natural), design, and in vitro/in vivo transformation efficiency.

Keywords: Gene delivery; Inorganic vectors; Nanoparticles; Non-viral vectors.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Internalization of non-viral vectors into cell and passage to nucleus through cytoplasm following endocytosis.
Figure 2
Figure 2
Schematic processes of LPD formation.
See this image and copyright information in PMC

References

    1. Rapti K, Chaanine AH, Hajjar RJ. Targeted gene therapy for the treatment of heart failure. Can J Cardiol. 2011;9(3):265–283. doi: 10.1016/j.cjca.2011.02.005. - DOI - PMC - PubMed
    1. Pouton CW, Seymour LW. Key issues in non-viral gene delivery. Adv Drug Deliv Rev. 2001;9(1–3):187–203. - PubMed
    1. Robbins PD, Ghivizzani SC. Viral vectors for gene therapy. Pharmacol Ther. 1998;9(1):35–47. doi: 10.1016/S0163-7258(98)00020-5. - DOI - PubMed
    1. Wang T, Upponi JR, Torchilin VP. Design of multifunctional non-viral gene vectors to overcome physiological barriers: dilemmas and strategies. Int J Pharm. 2012;9(1):3–20. doi: 10.1016/j.ijpharm.2011.07.013. - DOI - PubMed
    1. Hendriks WT, Ruitenberg MJ, Blits B, Boer GJ, Verhaagen J. Viral vector-mediated gene transfer of neurotrophins to promote regeneration of the injured spinal cord. Prog Brain Res. 2004;9:451–476. - PubMed